≡ Risteys
R8

Documentation Changelog GitHub Contact & Feedback

Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body

PheWeb

DM_EYE_OPER_VEGF_INJECT_VITR

No definition available.

Endpoint definition

↥
FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector

Check conditions None

356077

diagram downward connector
diagram bullet

Filter registries

Operations: NOMESCO codes ^CKD05

5538

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

5538

diagram downward connector

Check minimum number of events None

5538

diagram downward connector

Include endpoints None

5538

diagram downward connector
DM_EYE_OPER_VEGF_INJECT_VITR

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 5538 2654 2884
Unadjusted prevalence (%) 1.56 1.34 1.83
Mean age at first event (years) 69.67 70.46 68.95

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.05 3.04 [2.34, 3.95] 9.8e-17 608
15 years 0.01 1.19 [0.91, 1.58] 2.1e-1 233
5 years 0.00 2.85 [2.27, 3.57] 1.1e-19 300
1 year 0.00 3.24 [2.41, 4.36] 9.1e-15 73

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: DM_EYE_OPER_VEGF_INJECT_VITR – Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body
GWS hits:

Survival analyses between endpoints

↥

Plot

before Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body
after Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body

↥